Ekaterini Bitzioni

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Several clinical and preclinical studies have shown that desferrioxamine (DFO), in addition to iron chelation, demonstrates antiproliferative activities against some aggressive malignancies and leukemic cells. METHODS In this study, we investigated retrospectively the role of early DFO administration postallografting, in terms of relapse(More)
  • 1